Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 6/20 | 0.37 |
| ▸ | CCR5 | P51681 | 2/20 | 0.37 |
| ▸ | KDM6B | O15054 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31342987 | 0.89 | ALDH1A1 (0.42) | CYP3A4KMT2AKDM6BKDM4C | |
| SCHEMBL31342873 | 0.89 | ALDH1A1 (0.42) | CYP3A4KMT2AKDM6BKDM4C | |
| SCHEMBL31343033 | 0.88 | CYP3A4 (0.47) | CYP3A4TRPC6 | |
| SCHEMBL31343097 | 0.88 | CYP3A4 (0.40) | CYP3A4TRPC6CCR5KDM6BKDM4C | |
| SCHEMBL31342878 | 0.87 | CYP3A4 (0.51) | CYP3A4MEN1KMT2A | |
| SCHEMBL31342829 | 0.86 | GPR119 (0.43) | CYP3A4MEN1KMT2A | |
| SCHEMBL31343032 | 0.85 | TRPC6 (0.38) | CYP3A4TRPC6CCR5 | |
| SCHEMBL31342876 | 0.84 | CYP3A4 (0.51) | CYP3A4MEN1KMT2ATRPC6 | |
| SCHEMBL31342930 | 0.84 | TRPC6 (0.39) | CYP3A4TRPC6CCR5 | |
| SCHEMBL31343010 | 0.84 | KDM4C (0.37) | MEN1KMT2ATRPC6KDM6BKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049495-A1 | TERTIARY PYRIDYL AMINE MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYLINATION | GENENTECH, INC. (US) | 2025-03-06 | — | — | WO | disclosed |